Infectious Disease
HPV-related cervical cancer rates are falling after the vaccine is introduced
December 18, 2021
Read for 1 minute
Source / information
Published by:
Disclosure:
The authors do not report any relevant financial information.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
HPV-associated cervical cancer rates declined in women ages 15 to 39 in the United States after vaccine introduction, data from JAMA Pediatrics shows.
Tara Tabibi, BA, from St. Louis University School of Medicine, and colleagues performed a quasi-experimental analysis that compared the incidence and death rates of women with cervical cancer-related HPV.
Source: Adobe Stock.
The study compared incidence and mortality rates in women from January 2001 to December 2015 with rates from January 2010 to December 2017. Vaccination against HPV was first recommended in 2006 for women aged 11 to 26 years.
Tabibi and colleagues divided the study participants into three groups based on age – 15 to 24 years, 25 to 29 years and 30 to 39 years.
From 2001 to 2005, the incidence rates in the three age groups were 0.86, 6.08 and 13.6 per 100,000 cases, respectively. The mortality rates in the groups were 0.08, 0.57 and 1.95 per 100,000 cases, respectively.
From 2010 to 2017, the incidence rates in the three age groups were 0.54, 5.1 and 12.1 per 100,000 cases, respectively. The mortality rates in the groups were 0.04, 0.59 and 1.86 per 100,000 cases, respectively.
The incidence rates decreased in all three age groups, with the largest difference seen in 15- to 24-year-olds, who saw a decrease of 37.7% (95% CI, 42.24% to 32.75%) . There was a 16.16% decrease (95% CI, 19.45% to 12.69%) among participants aged 25 to 29 years and an 8.03% decrease among participants aged 30 to 39 years (95% CI, 9.9% to 6.12%).
“The current study expands knowledge by quantitatively comparing changes in the incidence of cervical cancer based on age-dependent vaccine suitability and providing clues for a vaccine-associated reduction in cervical cancer mortality,” wrote Tabibi.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio